ADDISON, Texas - MDB Capital Holdings, LLC (NASDAQ: MDBH), a venture platform known for its focus on deep technology companies, has announced a new collaboration with Mayo Clinic to develop a small molecule anti-senescence therapy aimed at longevity and preventing age-related diseases.
The partnership, announced today, leverages a patent and know-how agreement to advance research targeting senescent cells, which are linked to aging and chronic diseases.
Senescent cells, which cease to divide and accumulate with age, have been implicated in promoting chronic inflammation and various fibrotic conditions with limited treatment options. Research from Mayo Clinic has demonstrated the potential of the licensed molecule to selectively eliminate these cells, offering a substantial therapeutic opportunity to reverse fibrosis in multiple conditions.
Christopher Marlett, CEO and Co-Founder of MDB, expressed enthusiasm about the collaboration, emphasizing the company's commitment to addressing aging and related diseases. Dr. Andrew J. Haak, PhD, an Assistant Professor and Researcher at Mayo Clinic, echoed this sentiment, highlighting the scientific and clinical expertise that Mayo Clinic brings to the partnership.
The global market for longevity and anti-senescence therapies is projected to approach $45 billion by 2030, reflecting the significant interest and investment in this field. The financial interest of Mayo Clinic in the technology was disclosed, with the institution planning to reinvest any revenue back into its not-for-profit mission in patient care, education, and research.
MDB Capital, established in 1997, specializes in transforming "Big Ideas" into valuable public companies, often leveraging community-driven financings for pre-revenue, early-stage companies, and providing post-IPO offerings for public entities that meet their investment criteria.
The company operates a self-clearing broker-dealer and trading platform, as well as offering integrated intellectual property strategy consulting and legal services.
This collaboration represents a strategic move by MDB to harness cutting-edge research in the fight against age-related diseases, with the potential to improve patient outcomes across various conditions. The press release statement serves as the basis for this article.
In other recent news, MDB Capital Holdings has been active in both strategic partnerships and board appointments. The Dallas-based firm announced a significant agreement with the Mayo Foundation for Medical Education and Research, launching a new entity, MDB Minnesota One, Inc. This entity was created to develop a small molecule senescence platform under a license agreement with Mayo.
The deal includes an upfront license fee of $150,000 and development and funding milestones. MDB holds a 67% ownership stake in Minnesota One, and also entered into a Term Equity Purchase Agreement, which allows MDB to invest up to $5 million over the next five years in exchange for common stock.
In addition to this, MDB Capital Holdings has expanded its Board of Directors with the appointment of Daniel Torpey, a veteran in the financial sector. Torpey's extensive background in forensic accounting and integrity services is expected to strengthen the board's expertise in financial oversight and corporate governance.
His appointment as an independent director is in line with MDB Capital's commitment to corporate governance and shareholder value. These are the most recent developments in the ongoing evolution of MDB Capital Holdings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.